PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 61095

Title: Advanced small-bowel well-differentiated neuroendocrine tumours: An International Survey of Practice on 3rd line treatment

Reviewer's code: 02683307

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Doctor, Professor, Research Scientist

Reviewer's Country/Territory: South Korea

Author's Country/Territory: United Kingdom

Manuscript submission date: 2020-11-23

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2020-12-11 00:14

Reviewer performed review: 2020-12-31 10:34

Review time: 20 Days and 10 Hours

Scientific quality	[Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[Y] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This manuscript was written in order to get data of adequate 3rd line treatment for well differentiated small bowel neuroendocrine tumors. Effective method of online survey was used. The survey results showed that Everolimus was the most frequently used treatment. Most important factor for decision making are Ki67, rate of progression, functionality. These data can be utilized by oncologist with high value.